Qiagen N.V announced that it is ready to provide QuantiFERON-TB test kits to make up for the lack of availability of tuberculin for skin tests in Germany. This is in response to the recommendation of the German Central Committee against Tuberculosis (DZK) that public health services and clinics should use modern blood tests to screen at-risk children for tuberculosis (TB) infection during a shortage of tuberculin, a protein extract used in TB skin tests.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.48 USD | -0.21% | +3.53% | -5.12% |
07-09 | AlphaValue/Baader Europe Upgrades Qiagen to Buy from Add, Lifts PT | MT |
07-08 | Qiagen to Enhance the Identification of Human Remains of Indigenous People and African Americans | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.12% | 9.42B | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+45.77% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- Qiagen N.V. to Supply QuantiFERON-TB Tests to Ease Tuberculin Shortage in Germany